eXoZymes Inc., a Los Angeles-based developer of enzyme-based production processes, has selected contract research, development and manufacturing organization (CRDMO) Curia Global to transfer and scale its manufacturing process for N-trans-caffeoyltyramine (NCT).
The program is expected to begin in the fourth quarter of 2026 and will advance eXoZymes’ NCT process from pilot-scale validation toward larger scale manufacturing. The companies plan to establish a technical roadmap for subsequent production in 2027, according to the announcement.